- Report
- April 2024
- 305 Pages
Global
From €5179EUR$6,125USD£4,350GBP
- Report
- October 2024
- 184 Pages
Global
From €4287EUR$4,899USD£3,727GBP
- Report
- May 2024
- 224 Pages
Global
From €4200EUR$4,799USD£3,651GBP
- Report
- July 2023
- 205 Pages
Global
From €5163EUR$5,899USD£4,488GBP
- Report
- April 2022
- 121 Pages
Global
From €1662EUR$1,899USD£1,445GBP
- Report
- January 2022
- 310 Pages
Global
From €4200EUR$4,799USD£3,651GBP
- Report
- January 2022
- 151 Pages
Global
From €4200EUR$4,799USD£3,651GBP
- Report
- April 2022
- 131 Pages
Global
From €1137EUR$1,299USD£988GBP
- Report
- June 2021
- 193 Pages
Global
From €4200EUR$4,799USD£3,651GBP
- Report
- August 2019
- 519 Pages
Global
From €3937EUR$4,499USD£3,423GBP
- Report
- October 2024
- 295 Pages
Global
From €1310EUR$1,549USD£1,100GBP
- Report
- February 2026
Global
From €750EUR$918USD£675GBP
- Report
- February 2026
Global
From €600EUR$734USD£540GBP
- Report
- February 2026
Global
From €600EUR$734USD£540GBP
- Report
- February 2026
Global
From €450EUR$551USD£405GBP
- Report
- February 2026
Global
From €450EUR$551USD£405GBP
- Report
- February 2026
Global
From €450EUR$551USD£405GBP
- Report
- February 2026
Global
From €300EUR$367USD£270GBP
- Report
- February 2026
Global
From €300EUR$367USD£270GBP
- Report
- February 2026
Global
From €200EUR$245USD£180GBP

T Cell Therapies are a type of biotechnology that involves the use of a patient's own T cells to treat diseases. T cells are a type of white blood cell that play a key role in the body's immune system. T Cell Therapies involve the extraction of T cells from a patient, engineering them to recognize and attack specific targets, and then reintroducing them into the patient's body. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. It has also been used to treat autoimmune diseases, such as rheumatoid arthritis and Crohn's disease.
T Cell Therapies are a rapidly growing field of biotechnology, with many companies investing in research and development. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in developing and commercializing T Cell Therapies. Other companies, such as Gilead Sciences, Celgene, and Regeneron, are also investing in the field. Show Less Read more